US $13.92 billion raised for next 3 years to fight against AIDS, tuberculosis and malaria

Donors from across the world including governments, philanthropists and private firms have pledged just over $14 billion for the next three years to save 16 million lives and help end AIDS, tuberculosis and malaria by 2030. It was promised at the Sixth Replenishment Conference of Global Fund to fight against AIDS, tuberculosis and malaria (GFTAM) ..

Month: Current Affairs - October, 2019

Category: International Current Affairs

Topics: AIDS • Diseases • France • Global Fund • Global Fund to Fight AIDS Tuberculosis and Malaria • International • Malaria • Public health • Sixth Replenishment Conference • Tuberculosis

India to contribute $22 mn to GFTAM for 2020-22

India has announced contribution of $22 million to Global Fund for AIDS, TB and Malaria (GFTAM) for 6th Replenishment Cycle (for year 2020-22). This is an increase of 10% over the amount contributed by India in 5th cycle. Key Highlights India stands firm to its long-standing partnership with Global Fund and its commitment to eliminate ..

Month: Current Affairs - September, 2019

Topics: 6th Replenishment Cycle • Financing mechanism • GFTAM • Global Fund • Global Fund for AIDS TB and Malaria • healthcare • HIV/AIDS • India • Malaria • Sustainable Development Goals

India Health Fund to boost research on TB, malaria

The India Health Fund (IHF) launched by Tata Trusts in collaboration with Global Fund in August 2016 has come forward to financially support innovations and technologies designed to combat tuberculosis (TB) and malaria. The initiative aims to support new products and strategies that impact entire lifecycle of malaria and TB, from prevention to post-cure recovery. ..

Month: Current Affairs - February, 2018

Topics: Global Fund • India Health Fund • Science and Technology • Tata Trusts

Cipla wins Rs 1170 cr tender from Global Fund to supply HIV drugs

Indian pharmaceutical giant, Cipla has been awarded $188.95 million (around Rs. 1,172 crore) Contract by Global Fund to supply ARV (anti-retroviral) drugs. Cipla has been selected as a Panel Supplier for a supplier partnership agreement. This contract is effective from 1 January 2015 and will run for a period of three years i.e. till 2018. ..

Month: Current Affairs - February, 2015

Topics: ARV (anti-retroviral) drugs • Cipla • Current Affairs 2016 • Global Fund